Clinical Outcomes of neoadjuvant immunotherapy in NSCLC in the study

This study enrolled 144 stage IB-IIIB NSCLC patients who received neoadjuvant immunotherapy, withpathological response evaluable in 139 patients. The ORR in the cohort was 69.8%. Compared with non-MPR patients, MPR patients exhibited a significantly higher ORR (P = 0.031). However, no significant correlations were observed between ORR and pCR or DFS. (Figure 1A-B). Among evaluable patients, 59 (42.4%) achieved pCR and demonstrated significantly longer DFS versus non-pCR patients (P=0.039, Figure 1C), while 90 (64.7%) attained major pathological response (MPR) without significant DFS improvement (P=0.079, Figure 1D).